Uprima Clinical Trials and Studies
Buy UprimaUprima Information
Uprima Clinical Trials and Studies
In clinical studies, Uprima was administered to men with organic, psychogenic, or mixed etiology erectile dysfunction, and was evaluated for its ability to produce an erection firm enough for intercourse. Initial Uprima clinical studies included patients with controlled hypertension and diabetes (type I and type II). TAP has also evaluated Uprima in patients following nerve-sparing radical prostatectomy.
In addition, a unique aspect of TAP's Uprima clinical studies was the assessment of patients' partners for satisfaction. This assessment showed corroboration of findings from the patient.
The most commonly reported Uprima side effect was nausea. Of the nausea reported in the NDA clinical studies, most incidences were mild to moderate in severity.
The manufacturer of Uprima makes the following claim, which has not been substantiated by The Pharma-Help Team:
Once Uprima is dissolved under the tongue, clinical test have shown that 34% of erections occurred within 10 minutes and 71% of erections occurred within 20 minutes. That puts the average time to the onset of an Uprima erection at 18-19 minutes - 200% faster than a leading competitor brand.
Buy Uprima